Pharmacogenomic and Pharmacometabolomic Biomarkers of the Efficacy and Safety of Antidepressants: Focus on Selective Serotonin Reuptake Inhibitors

被引：0
作者：
A. E. Gareeva [1 ]
L. S. Borodina [2 ]
S. A. Pozdnyakov [3 ]
I. F. Timerbulatov [4 ]
机构：
[1] Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa
[2] Kemerovo State University, Kemerovo
[3] Russian Medical Academy of Continuous Professional Education, Russian Ministry of Health, Moscow
[4] Republican Narcology Dispenser No. 1, Ministry of Health of the Republic of Bashkortostan, Ufa
[5] Moscow Scientific and Applied Narcology Center, Moscow City Health Department, Moscow
[6] Usoltsev Central Clinical Psychiatric Hospital, Moscow
[7] Russian Medical University, Russian Ministry of Health, Moscow
来源：
Neuroscience and Behavioral Physiology | 2024年 / 54卷 / 8期
关键词：
antidepressants; pharmacogenomics; pharmacometabolomics; selective serotonin reuptake inhibitors;
D O I：
10.1007/s11055-024-01716-5
中图分类号：
学科分类号：
摘要：
The efficacy and safety of psychopharmacotherapy with antidepressants is of great medical importance. The search for clinical and biological predictors for the selection of optimal psychopharmacotherapy with antidepressants is under active investigation throughout the world. Most studies address the search for associations between polymorphic variants of genes and the efficacy and safety of therapy. However, data on patients’ genetic polymorphisms are often insufficient for predicting the efficacy and safety of a drug. Contemporary research on the personalization of pharmacotherapy should include not only genetic, but also phenotypic biomarkers. This is important because genotyping, for example, cannot accurately predict the real metabolic activity of an isoenzyme. Successful treatment of depression remains a complex task; between-individual differences in responses to antidepressants are common. About half of patients with depressive disorders do not respond to the first attempt at antidepressant therapy. Serious side effects in pharmacotherapy with antidepressants and discontinuation of treatment due to intolerance are associated with lack of therapeutic efficacy. This review presents results from the latest studies of “omics” biomarkers of the efficacy and safety of antidepressants. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
引用
收藏
页码：1205 / 1214
页数：9
相关论文
共 86 条
  • [71] Baudry A., Mouillet-Richard S., Schneider B., Et al., miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants, Science, 329, 5998, pp. 1537-1541, (2010)
  • [72] Ding Y., Zhong M., Qiu B., Et al., Abnormal expression of miR-135a in patients with depression and its possible involvement in the pathogenesis of the condition, Exp. Ther. Med, 22, 1, (2021)
  • [73] Fiori L.M., Lopez J.P., Richard-Devantoy S., Et al., Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response, Int. J. Neuropsychopharmacol, 20, 8, pp. 619-623, (2017)
  • [74] Lopez J.P., Lim R., Cruceanu C., Et al., miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment, Nat. Med, 20, 7, pp. 764-768, (2014)
  • [75] He S., Liu X., Jiang K., Et al., Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder, J. Psychiatr. Res, 78, pp. 65-71, (2016)
  • [76] Ahmadimanesh M., Etemad L., Morshedi Rad D., Et al., Effect of citalopram and sertraline on the expression of miRNA-124, 132, and 16 and their protein targets in patients with depression, Iran. J. Basic Med. Sci., 26, 7, pp. 820-829, (2023)
  • [77] Fang Y., Qiu Q., Zhang S., Et al., Changes in miRNA-132 and miR-124 levels in non-treated and citalopram-treated patients with depression, J. Affect. Disord, 227, pp. 745-751, (2018)
  • [78] Mouillet-Richard S., Baudry A., Launay J.M., Kellermann O., MicroRNAs and depression, Neurobiol. Dis, 46, 2, pp. 272-278, (2012)
  • [79] Israel-Elgali I., Pan H., Oved K., Et al., Impaired myelin ultrastructure is reversed by citalopram treatment in a mouse model for major depressive disorder, J. Psychiatr. Res, 166, pp. 100-114, (2023)
  • [80] Simeoli R., Montague K., Jones H.R., Et al., Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma, Nat. Commun, 8, 1, (2017)
123456789